Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A known ✓ | P46098 | 6/20 | 0.74 |
| ▸ | CHRNA7 known ✓ | P36544 | 15/20 | 0.67 |
| ▸ | HTR3E known ✓ | A5X5Y0 | 1/20 | 0.60 |
| ▸ | HTR3B known ✓ | O95264 | 1/20 | 0.60 |
| ▸ | HTR3D known ✓ | Q70Z44 | 1/20 | 0.60 |
| ▸ | HTR3C known ✓ | Q8WXA8 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15796777 | 0.99 | HTR3A (0.75) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| SCHEMBL1101796 | 0.99 | HTR3A (0.75) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| Hydrochloric Acid SCHEMBL1090845 | 0.88 | HTR3A (0.77) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| Hydrochloric Acid SCHEMBL1091798 | 0.87 | HTR3A (0.71) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| SCHEMBL1101986 | 0.87 | HTR3A (0.78) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| Hydrochloric Acid SCHEMBL1091297 | 0.87 | HTR3A (0.75) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| SCHEMBL1101760 | 0.86 | HTR3A (0.72) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| Hydrochloric Acid SCHEMBL1091469 | 0.86 | HTR3A (0.98) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| SCHEMBL1459342 | 0.86 | HTR3A (0.76) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| SCHEMBL1101795 | 0.86 | HTR3A (0.76) | HTR3ACHRNA7HTR3EHTR3BHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10196388-B2 | Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2019-02-05 | — | — | US | claimed |
| US-20180127409-A1 | AZABICYCLIC CARBAMATES AND THEIR USE AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-10 | — | — | US | claimed |
| US-9714242-B2 | Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-07-25 | — | — | US | claimed |
| US-9714242-B2 | Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-07-25 | — | — | US | disclosed |
| US-20150065537-A1 | AZABICYCLIC CARBAMATES AND THEIR USE AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-03-05 | — | — | US | disclosed |
| US-8772511-B2 | Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-07-08 | — | — | US | disclosed |
| US-20130060039-A1 | AZABICYCLIC CARBAMATES AND THEIR USE AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | BAYER SCHERING PHARMA AG (DE) | 2013-03-07 | — | — | US | disclosed |
| US-8153799-B2 | Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2012-04-10 | — | — | US | disclosed |
| US-20100324085-A1 | AZABICYCLIC CARBAMATES AND THEIR USE AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | BAYER SCHERING PHARMA AG (DE) | 2010-12-23 | — | — | US | disclosed |
| US-7795453-B2 | Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-09-14 | — | — | US | disclosed |
| EP-1527073-B1 | BENZOTHIOPHENE UREA, BENZOFURANE UREA, AND INDOLE UREA, AND USE OF THE SAME AS ALPHA-7 ACHR AGONISTS | BAYER HEALTHCARE AG (DE) | 2007-08-22 | — | — | EP | disclosed |
| US-20060106096-A1 | Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists | BAYER HEALTH AG (DE) | 2006-05-18 | — | — | US | disclosed |
| EP-1527073-A1 | BENZOTHIOPHENE UREA, BENZOFURANE UREA, AND INDOLE UREA, AND USE OF THE SAME AS ALPHA-7 ACHR AGONISTS | Bayer HealthCare AG (DE) | 2005-05-04 | — | — | EP | disclosed |
| WO-2004013136-A1 | BENZOTHIOPHENE UREA, BENZOFURANE UREA, AND INDOLE UREA, AND USE OF THE SAME AS ALPHA-7 ACHR AGONISTS | BAYER HEALTHCARE AG (DE) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324085-A1 | AZABICYCLIC CARBAMATES AND THEIR USE AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | CHRNA7, CHRNA5, CHRNA4 | HTR3A 452/4885CHRNA7 1/4885HTR3E 1133/4885 |
| US-20150065537-A1 | AZABICYCLIC CARBAMATES AND THEIR USE AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | CHRNA7, CHRNA5, CHRNA4 | HTR3A 452/4885CHRNA7 1/4885HTR3E 1133/4885 |
| US-20180127409-A1 | AZABICYCLIC CARBAMATES AND THEIR USE AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | CHRNA7, CHRNA5, CHRNA4 | HTR3A 452/4885CHRNA7 1/4885HTR3E 1133/4885 |
| US-20060106096-A1 | Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists | CHRNA7, CHRNA5, CHRNA4 | HTR3A 498/4885CHRNA7 1/4885HTR3E 1265/4885 |
| US-20130060039-A1 | AZABICYCLIC CARBAMATES AND THEIR USE AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | CHRNA7, CHRNA5, CHRNA4 | HTR3A 452/4885CHRNA7 1/4885HTR3E 1133/4885 |
| US-10196388-B2 | Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists | CHRNA7, CHRNA5, CHRNA4 | HTR3A 452/4885CHRNA7 1/4885HTR3E 1133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.